Abstract
Phase II trials are an important component of drug development in oncology. Their objective is to screen for preliminary signals of efficacy of new anticancer agents and to provide further information on drug toxicity. Many different phase II trial designs have been envisioned and utilized according to cancer behavior, type of drug effects on tumors, study endpoints, and treatment settings. The trials are generally classified as either single- or multiple-arm non-randomized trials or randomized phase II trials. Within each group, there are numerous different designs, with the most common ones being single-arm phase II trials, biomarker-driven trials, randomized “pick the winner” trials, randomized controlled phase II studies, randomized discontinuation trials, and crossover studies. The aim of this chapter is to provide an overview of the different designs of phase II cancer trials and to discuss the advantages and disadvantages of each design.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Riechelmann RP, Dounaevskaia V, Krzyzanowska MK. Quality of reporting primary outcomes in phase II cancer trials. J Clin Oncol. 2008;26(33):5486–8.
Saad ED, Sasse EC, Borghesi G, et al. Formal statistical testing and inference in randomized phase II trials in medical oncology. Am J Clin Oncol. 2013;36(2):143–5.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2017;45(2):228–47.
Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002;8(4):935–8.
Cassileth BR. Clinical trials: time for action. J Clin Oncol. 2003;21(5):765–6.
Adjei AA, Christian M, Ivy P. Novel designs and end points for phase II clinical trials. Clin Cancer Res. 2009;15(6):1866–72.
Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623–32.
Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2017;51(5):587–94.
Mariani L, Marubini E. Content and quality of currently published phase II cancer trials. J Clin Oncol. 2000;18(2):429.
Gehan EA. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961;13:346–53.
Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38(1):143–51.
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.
Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69(12):1375–81.
Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53.
Renfro LA, An M-W, Mandrekar SJ. Precision oncology: a new era of cancer clinical trials. Cancer Lett. 2017;387:121–6.
Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23(28):7199–206.
da Rocha Lino A, Abrahão CM, Brandão RM, Gomes JR, Ferrian AM, Machado MC, Buzaid AC, Maluf FC, Peixoto RD. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. J Gastrointest Oncol. 2015;6(5):511–5. https://doi.org/10.3978/j.issn.2078-6891.2015.041.
Amery W, Dony J. A clinical trial design avoiding undue placebo treatment. J Clin Pharmacol. 1975;15:674–9.
Stadler WM, Rosner G, Small E, et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma—CALGB 69901. J Clin Oncol. 2005;23(16):3726–32.
Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505–12.
Freidlin B, Simon R. Evaluation of randomized discontinuation design. J Clin Oncol. 2005;23(22):5094–8.
Schaid DJ, Wieand SAM, Therneau TM. Optimal two-stage screening designs for survival comparisons. Biometrika. 1990;77(3):507–13.
Korn EL. Design issues in randomized phase II/III trials. J Clin Oncol. 2012;30:667–71.
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Riechelmann, R.P., Araújo, R.L., Hinke, A. (2018). The Many Different Designs of Phase II Trials in Oncology. In: Araújo, R., Riechelmann, R. (eds) Methods and Biostatistics in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-71324-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-71324-3_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-71323-6
Online ISBN: 978-3-319-71324-3
eBook Packages: MedicineMedicine (R0)